Aprea Therapeutics, Inc. 8-K

What Happened Aprea Therapeutics, Inc. announced the results of its June 16, 2026 annual meeting. Shareholders elected three Class I directors (Marc Duey, Richard Peters, M.D., and Bernd R. Seizinger, M.D., Ph.D.), ratified EisnerAmper LLP as the 2026 auditor, and approved an amendment authorizing the Board to effect a reverse stock split of the common stock at a ratio between 1-for-3 and 1-for-8 (exact ratio and timing to be set by the Board). 8,268,451 of 12,382,776 shares (approximately 66.8%) were represented, constituting a quorum.

Key Details

• Director elections: Marc Duey (5,817,488 for; 64,578 withheld; 2,386,385 broker non-votes); Richard Peters, M.D. (5,824,115 for; 57,951 withheld; 2,386,385 broker non-votes); Bernd R. Seizinger, M.D., Ph.D. (5,495,110 for; 386,956 withheld; 2,386,385 broker non-votes).
• Auditor ratified: EisnerAmper LLP approved (8,107,969 for; 44,299 against; 116,183 abstaining).
• Reverse stock split authorized: Proposal approved (8,038,052 for; 210,751 against; 19,648 abstaining); Board may elect any ratio between 1-for-3 and 1-for-8 and timing.
• Executive pay advisory votes: Say-on-pay approved (5,777,837 for; 78,853 against; 25,376 abstain; 2,386,385 broker non-votes). Frequency vote: shareholders chose annual votes (1 year: 4,276,181; 3 years: 1,056,208; 2 years: 22,984; abstain: 526,693). Adjournment option approved (8,056,154 for).

Why It Matters The reverse stock split authorization gives the Board flexibility to reduce the number of outstanding shares (between 3:1 and 8:1), which will change the per‑share metrics and share count if the Board elects to implement it; the measure does not alter the authorized share count and has not yet been implemented. Director elections and auditor ratification provide continuity in governance and financial oversight. The advisory (non‑binding) approval of executive compensation and an annual say‑on‑pay vote reflect shareholder endorsement but do not legally compel changes. Investors should note the vote tallies and the presence of substantial broker non‑votes on certain items, which affected the voting outcome for some proposals.